AVXL   $9.03  6.61% Market Closed After Close 9.1 0.78%

Anavex Life Sciences Corp
Last Events:

2023-08-09 Signal in MACD changed from bullish reversal to bearish recovery. Oscillator MACD is in the negative territory it's higher than the signal line and falls. These factors mean that negative mood prevails, but this trend does not have a significant strength. Last signal: main and signal line crossing.

2023-08-09 Signal in EMA20 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-06 Signal in Stochastic changed from bullish to bearish reversal. The stochastic indicator is in the upper part of the neutral territory and left the overbought territory. These factors indicate that perhaps the upside trend is coming to an end price will probably head south Last signal: main and signal line crossing.

2023-08-06 Signal in RSI changed from bullish to bearish. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-05 Signal in RSI changed from bearish weakening to bullish. RSI indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: exit from the overbought zone.

2023-08-05 Trend Power changed from almost flat to slow.

2023-08-04 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-08-04 Signal in EMA20 changed from bearish reversal to bullish reversal. The price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.


Current temperature: 8.44
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 4
Target Price Mean 35.47
Mean unverified/preliminary 35.47 / 35.47
Target Price Low / High 15.00 / 46.00
Median / STD DEV 40.45 / 13.90
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy ActivelyBuy ActivelyBuy
rsi ActivelyBuy Buy ActivelyBuy
macd None None None
stoch ActivelyBuy None None
ma20 Buy ActivelyBuy None
ma50 ActivelyBuy None None
ma100 Buy ActivelyBuy ActivelyBuy
Candlestick PatternNov. 8, 2024 Evening Star - is composed of a white candlestick followed by a short candlestick, which characteristically gaps up whenuptrend is in progress. A third candlestick is black. Considered to be a bearish reversal pattern.
ISIN US0327973006
ceo Dr. Christopher U. Missling M.B.A., M.S., Ph.D.
Website https://www.anavex.com
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.